UCB has committed $2 billion toward expanding Candid’s T-cell engager platform, signaling a major push into engineered cell-engaging therapies for autoimmune disease. The investment underscores how European pharma is moving aggressively from early proof-of-concept toward larger-scale clinical programs in a modality that has drawn both high expectations and technical complexity.